Use of surrogate end‐points such as progression‐free survival (PFS) and other time‐to‐
event (TTE) end‐points is common in multiple myeloma (MM) clinical trials. This systematic …

Background As the treatment for metastatic breast cancer (MBC) often includes sequential
lines of therapy, data on post-protocol treatment in clinical trials are valuable in the …

Background Suboptimal treatment upon progression may affect overall survival (OS) results
in oncology randomized controlled trials (RCTs). We aim to assess the proportion of trials …

Background Because patients with newly diagnosed multiple myeloma (NDMM) do not
always receive any treatment beyond first-line (1L) therapy, it is imperative that patients …

Background: Many participants in clinical trials supporting US Food and Drug Administration
(FDA) drug approvals are recruited from outside the United States, including from low-and …

The ethical permissibility of randomized controlled trials (RCTs) depends on clinical
equipoise at the time of trial enrollment—the existence of uncertainty about which treatment …

Background: For multiple myeloma (MM), the proportions of patients reaching the
subsequent line of therapy (LOT) decline gradually and real-world data describing the …

Median overall survival for patients with newly diagnosed multiple myeloma may surpass
ten years. Nonetheless, many patients face considerable treatment-related morbidity and …

A lot of attention is rightfully given to racial and socioeconomic disparities in cancer care. 1 It
is certain that disadvantaged groups have less access to lifeextending oncology care, with …

Introduction Prior studies have evaluated the level of evidence behind treatment options
listed in the National Comprehensive Cancer Network (NCCN) guidelines, but no study has …